Applications of Casanovo#
De novo peptide sequencing has diverse applications in proteomics, ranging from antibody sequencing to paleoproteomics. You can find some papers that use Casanovo for de novo sequencing in different domains below. Contact us with your applications of Casanovo to feature your research on this page by opening a Github issue here with a link to the paper and a one-sentence description of how Casanovo is being used.
Comprehensive evaluation of peptide de novo sequencing tools for monoclonal antibody assembly (Beslic et al., Briefings in Bioinformatics, 2023): Casanovo is used to de novo sequence monoclonal antibodies and shown to outperform other de novo sequencing tools.
Giant genes are rare but implicated in cell wall degradation by predatory bacteria (West-Roberts et al., bioRxiv, 2023): Casanovo is used to de novo sequence giant proteins with up to 85,804 amino acids in a metagenomic setting.
Comprehensive assembly of monoclonal and mixed antibody sequences (Jiang et al., bioRxiv, 2024): Casanovo is used to sequence four human and three murine COVID-19 neutralizing antibody datasets, as well as to sequence a commercial monoclonal antibody with undetermined sequence.
Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases (Chernigovskaya et al., bioRxiv, 2024): Casanovo is used to profile the sequence diversity of circulating monoclonal antibody repertoire.
De novo assembled databases enable species-specific protein-based stable isotope probing of microbiomes without prior knowledge of the community composition (Klaes et al., bioRxiv, 2024): Casanovo is used to de novo sequence microbial peptides to enable species-specific protein-based stable isotope probing.
Cryo-EM reveals that cardiac IGLV6-derived AL fibrils can be polymorphic (Bassett et al., bioRxiv, 2024): Casanovo is used to de novo sequence fibrils, i.e. antibody light chain aggregates.
Last updated on March 14, 2025.